iTeos plans to shut down operations after cancer therapy setback
28/05/2025 13:40
May 28 (Reuters) - Drug developer iTeos Therapeutics ITOS.O said on Wednesday it plans to wind down its operations and explore selling its assets, including experimental cancer treatments and an obesity program. Earlier this month, Britain's GSK GSK.L and iTeos Therapeutics said they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing in two studies. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shreya Biswas) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on iTeos Therapeutics
See all newsIteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Brief: Iteos Therapeutics Enters Into Agreement To Be Acquired By Concentra Biosciences For $10.047 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-Nvidia, Salesforce, Kestrel Group
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Sonic Automotive